Johnson & Johnson (JNJ) and AstraZeneca (AZN) separately are stopping tests of experimental...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

Johnson & Johnson (JNJ) and AstraZeneca (AZN) separately are stopping tests of experimental pain drugs because of concerns over bone damage. Combined with earlier suspensions by Pfizer (PFE) and Regeneron (REGN), the moves may mean the anti-nerve growth factor drug class - once expected to generate $11B in annual revenues - is a "tainted class."